$GRDN

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.

Guardian Pharmacy Services (NYSE:GRDN) rose 3.2% pre-open after reporting Q2 2026 results ahead of forecasts. Adjusted EPS was $0.29 vs $0.23 expected, and revenue was $351.8M, up 2% YoY. The company raised full-year 2026 revenue guidance to $1.43–$1.45B. Adjusted EBITDA rose 19% to $29.7M.

Guardian Pharmacy Services Inc. (GRDN) reported Q2 profit of $21.9 million, or 34 cents per share. Adjusted earnings were 29 cents versus a Zacks-surveyed analyst average of 26 cents. Revenue was $351.8 million. The company forecast full-year revenue of $1.43 billion to $1.45 billion.

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d160709dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”)

Guardian Pharmacy Services (NYSE: GRDN) said it opened its first Kentucky physical location, Guardian Pharmacy of Kentucky, in Lexington. The LTC pharmacy will serve assisted living, skilled nursing, behavioral health, and intellectual and developmental disability organizations statewide. The company cited increased demand and said the facility uses automation to prepare medications, led by Tom Mullaney as president.

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001802255 0001802255 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

Guardian Pharmacy Services, Inc. (GRDN) director Steven D. Cosler was granted 4,028 restricted stock units (RSUs) as part of a compensation package. This award, valued at $0.00 per share, increases his direct holdings to 29,012 Class A common shares. The transaction was reported in a Form 4 filing, indicating a routine equity grant rather than a market purchase or sale.

Guardian Pharmacy Services has released its financial results for the first quarter of 2026, including key financial metrics like revenue and earnings per share. The company also announced a revision to its full-year 2026 financial guidance, reflecting updated expectations based on its performance and current market conditions. This adjustment provides an updated outlook for the remainder of the year.

Raymond James raised its price target on Guardian Pharmacy Services Inc. (NYSE:GRDN) to $40 from $35, maintaining an Outperform rating after strong fourth-quarter 2025 results. The company exceeded revenue and adjusted EBITDA estimates, driven by its successful flu vaccine program. Guardian Pharmacy also raised its 2026 guidance for adjusted EBITDA to $120-124 million, reflecting continued growth and improved operational execution, leading Truist Securities to also increase its price target.

Guardian Pharmacy Services, Inc. (GRDN) is expanding its 13% market share in the assisted living pharmacy sector. The company is achieving this through a strategy of organic growth, disciplined mergers and acquisitions, and a technology-enabled service model. Strong financial performance, high adoption rates, and proactive engagement with regulators are positioning GRDN for continued growth amidst favorable demographic trends.